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Evidence from 3-month-old infants 
shows that a combination of 
postnatal feeding and exposures  
in utero shape lipid metabolism
Samuel Furse  1, Stuart G. Snowden1, Laurentya Olga  2, Philippa Prentice2, Ken K. Ong2,3, 
Ieuan A. Hughes2, Carlo L. Acerini2, David B. Dunger  2 & Albert Koulman  1,3
We tested the hypothesis that both postnatal feeding and conditions in utero affect lipid metabolism in 
infants. Infants who experienced restrictive growth conditions in utero and others exposed to maternal 
hyperglycaemia were compared to a control group with respect to feeding mode. Dried blood spots 
were collected from a pilot subset of infant participants of the Cambridge Baby Growth Study at 3mo. 
Groups: (a) a normal gestation (control, n = 40), (b) small for gestational age (SGA, n = 34) and (c) whose 
mothers developed hyperglycaemia (n = 59). These groups were further stratified by feeding mode; 
breastfed, formula-fed or received a mixed intake. Their phospholipid, glyceride and sterol fractions 
were profiled using direct infusion mass spectrometry. Statistical tests were used to identify molecular 
species that indicated differences in lipid metabolism. The abundance of several phospholipids 
identified by multivariate analysis, PC(34:1), PC(34:2) and PC-O(34:1), was 30–100% higher across 
all experimental groups. SM(39:1) was around half as abundant in in utero groups among breastfed 
infants only. The evidence from this pilot study shows that phospholipid metabolism is modulated by 
both conditions in utero and postnatal feeding in a cohort of 133 Caucasian infants, three months post 
partum.
There is mounting evidence that conditions in utero can have profound and long-lasting effects on infant growth 
and metabolism. Recent studies in animal models have indicated that maternal diet and obesity are associ-
ated with cardio-vascular dysfunction1,2, inflammation of adipose tissue3, insulin resistance4–6, adiposity5, 
non-alcoholic fatty liver disease7 and even modulated nutrient acquisition8 in their offspring. Exercise has also 
been shown to rescue obese mothers’ insulin sensitivity and that of her male offspring9.
Similarly, a variety of exposures during pregnancy have been associated with birth outcomes in humans. It has 
been known for some time that factors such as smoking and a high caffeine intake during gestation lead to a lower 
birth weight in humans10–12. Both maternal obesity13–15 and gestational diabetes16–19 in humans typically lead to 
a higher birth weight, and higher rate of stillbirth20,21. Furthermore, babies small and large for gestational age are 
at increased risk of metabolic complications in later life22,23, which is consistent with the evidence from animal 
models of diet-induced obesity and gestational diabetes mellitus (GDM)1–3,5.
However, it is also becoming evident that dietary exposure in early life can have a profound effect on infant 
development in humans. Studies of the lipid profile in infant circulation show that this reflects feeding and corre-
lates with development in the first years24–26, and hints that lipid metabolism is linked to infant development. This 
raises questions about how dysregulation of metabolism later in life is associated with conditions in utero, and 
how it might be detected early in life in order to facilitate the timing of appropriate intervention.
The importance of these questions is underscored by epidemiological evidence that the maternal hyperglycae-
mia (MHG) associated with GDM affects 8–24% of pregnancies in the UK, and is rising27. The concentration of 
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glucose in the circulation of women who develop GDM is typically abnormally high due to decreased sensitivity 
to insulin and impaired insulin secretion. This results in higher placental transfer of glucose can contribute to 
more rapid growth of the foetus in utero. By contrast, there continue to be large numbers of babies who are born 
at a low birth weight. ‘Small for gestational age’ (SGA), based on sex and gestation-corrected size at birth, is often 
used to identify babies who had poor growth in utero. Several pregnancy-related maternal and placental factors 
may be involved in an infant falling into this group28,29, and such infants usually show rapid growth after birth30. 
Although much phenotypical data about both SGA and MHG infants has been collected, the metabolism driving 
these phenotypes is not clear.
This is particularly striking as several phospholipids in infant circulation correlate with their growth24,25. This 
raises questions about how infants of normal and high birth weight from GDM pregnancies differ, and whether 
the metabolism that arises from all normal-weight births are similar. The combination of the risks to health of 
both low- and high-weight births, the evidence that the phospholipid and triglyceride profiles in the circulation 
of infants is heavily dependent upon how they are fed24,25 and correlate with their growth, and evidence that 
conditions in utero shape infant growth, led us to the hypothesis that the metabolic response to diet in early life is 
modified by exposures in utero.
To address this question, we assessed the circulating phospholipid and triglyceride profile of infants from 
three groups stratified by conditions in utero, and within each group we compared the mode of feeding (breastfed, 
formula-fed, or mixed-fed). The three in utero groups of infants included were (a) born at low birth weight for ges-
tational age (SGA), (b) exposed to maternal hyperglycaemia (MHG) but with a normal birth weight, or (c) Controls 
(normal birth weight and no MHG). The groups were otherwise homogeneous, none of the mothers of SGA babies 
had hyperglycaemia. Each group comprised individuals who were breastfed, formula-fed or received a mixed 
intake. This allowed us to compare the in utero exposure across different post natal (first 3mo of life) feeding types, 
and also feeding types across infants exposed to different conditions in utero. This was designed to give an insight 
into the way both post natal (first 3mo of life) feeding and conditions in utero affected the observed lipid metabo-
lism at three months of age. The method for profiling the phospholipids and triglycerides present (mass spectrom-
etry) was chosen to identify individual metabolites in order to characterise differences in lipid metabolism.
Results
Augmentation of reported data. In order to identify all possible lipid/triglyceride variables that may be asso-
ciated with the phenotypical or diagnostic difference between groups, we judged that molecular species identified in 
both positive and negative mode should be used. We therefore augmented data from a previous study, that was based 
only on positive ionisation mode24,25, with the appropriate lipid profiles from signals collected in negative ionisa-
tion mode. Statistical tests (Principal component analysis followed by T-tests) performed on this augmented dataset 
showed that it exhibits the same trends as the positive mode data alone; there is a clear separation between the phos-
pholipid and glyceride profiles of the three feeding groups tested (breastfed infants, formula-fed infants and infants 
receiving a mixed intake), with the mixed feeding group lying between the other two (Supplementary Fig. 1A). We 
then examined the abundance of biomarkers of feeding identified previously in additional infants, who form the 
normal birth weight Control group of the current study, Supplementary Fig. 1B. This approach is used to validate the 
control group of this study with that used in previous work. Both the magnitude and pattern of abundance of these 
biomarkers of feeding type appears to be similar in this independent Control group (Supplementary Fig. 2).
Influence of feeding mode across in utero groups. The hypothesis of this study is that both postnatal 
feeding and conditions in utero influence the lipid metabolism observed in infants at 3mo. In order to test this, 
we first stratified the participants only by the in utero groups, i.e. those who were small for gestational age (SGA), 
those who were exposed to maternal hyperglycaemia in utero and those of healthy pregnancies, and sought to 
identify the variables that distinguish the groups without reference to how the participants were fed. A Random 
Forest classification found no molecular species that distinguished the utero groups (SGA, MHG, Control). This 
suggests that feeding mode has a more pronounced influence on the lipids in circulo and thus we stratified the 
participants by the feeding mode as well as by conditions in utero. This approach allows us to distinguish any 
effects of conditions in utero from those of feeding mode.
Stratification of the participants by both feeding type and conditions in utero. The evidence that 
the in utero groups alone did not dominate the lipid metabolism at 3mo led us to stratify the infants according to 
feeding type (breastfed, mixed, formula-fed) as well as the conditions they were experienced to in utero (giving 
rise to the SGA, MHG and control groups). This gave nine groups. In order to test whether lipid metabolism was 
different in the exposed groups (SGA, MHG), we compared exposed and control groups of the same feeding 
type. A supervised statistical test (sPLS-DA) was used to identify (a) the individual variables (molecular species) 
that distinguished, for example, the breastfed MHG group from the breastfed Control group and (b) the feeding 
groups within the exposed groups (e.g. breast and formula fed individuals from the MHG group). This structure 
was adopted in order to compare individuals who differed in either conditions in utero or by feeding mode.
Variables indicating shifts in lipid metabolism in SGA and MHG infants. None of the species iden-
tified in previous work25 was identified as a variable that drove the distinctions between different feeding types 
in SGA infants (Supplementary Fig. 3A, loading values in table). The lipid species that were identified as distin-
guishing the breastfed from formula fed SGA infants (SM(36:2) and SM(34:2)) were structurally similar to those 
found previously. Several lipid species distinguish MHG infants from controls (Table 1). However, three of these 
variables are also identified as the three most important variables for distinguishing the three feeding groups of 
MHG infants from one another: PC(34:2), SM(32:1) and SM(39:1) (Supplementary Fig. 3B).
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Lipid
SGA MHG
Breast-fed Mixed-fed Formula-fed Breast-fed Mixed-fed Formula-fed
PC1 PC2 PC1 PC2 PC1 PC2 PC1 PC2 PC1 PC2 PC1 PC2
PC(34:1) 
& 
PE(37:1)
0.532 −0.176 0.599 −0.254 0.549 −0.133 0.566 −0.254 0.597 −0.269 0.573 −0.268
PC(34:2) 0.489 0.230 0.356 −0.095 0.403 −0.312 0.389 −0.028 0.450 −0.094 0.385 −0.290
PC(38:4) 
& 
PE(41:4)
0.041 −0.030 0.039 −0.032 0.034 −0.031 0.049 −0.006 0.053 0.104 0.003 −0.041
PC-
O(34:1) & 
PC-
P(34:0)
0.020 −0.015 0.023 −0.013 0.021 0.002 0.022 −0.017 0.025 −0.012 0.022 −0.006
SM(36:2) 0.015 −0.010 0.006 −0.002 0.008 −0.003 0.014 0.001 0.008 0.012 0.007 0.009
SM(34:2) 0.014 0.000 0.001 0.009 0.002 0.010 0.009 0.010 0.006 0.015 0.008 0.019
SM(32:1) 0.008 −0.036 0.014 0.039 0.001 0.061 0.009 0.005 0.020 0.020 0.012 0.018
PC-
O(36:4) & 
PC-
P(36:3)
0.003 −0.002 0.001 −0.001 0.004 −0.004 0.005 −0.004 0.007 0.009 0.002 0.006
SM(39:1) −0.009 −0.008 −0.011 0.011 −0.013 0.016 −0.007 0.001 −0.006 0.005 −0.009 0.017
Table 1. Loading values for candidate biomarkers. Loading values generated by PCAs for the candidate 
biomarkers identified by sPLS-DA. Each exposed group (e.g. SGA-breastfed) tested against the appropriate 
control group (e.g. Control-breastfed). Loading values reflect the ranking of the variables by the (unsupervised) 
test. Note that the quantified rankings are only valid within principal components and thus cannot be compared 
between the groups. This test indicated that similar variables to those identified in Fig. 2 were important.
Figure 1. The abundance of candidate biomarkers in infants with normal conditions in utero as well as in 
SGA and MHG. Only these four lipids passed FDR based on a Bonferroni adjusted significance threshold. 
Panel (A) PC(34:2), isobaric with PE(37:2); (B) PC(34:1), isobaric with PE(37:1); (C) PC-O(34:1), isobaric 
with PC-P(34:0); (D) SM(39:1). No. variables = 340. p-Values for Bonferroni corrected T-test: for dependent 
variables = 0·00271 (marked*) and independent variables = 0·000147 (marked**) respectively.
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Identification of candidate biomarkers (CBMs). In order to identify CBMs for differences in lipid 
metabolism from the variables identified by the sPLS-DA, the abundance of the molecular species must also 
be considered. The abundances of the variables across the various groups were calculated (mean of all values in 
each group) and T-tests applied in order to quantify the significance of the difference in the mean of abundance 
in exposed and control groups. The p-value cut offs used were 0·00271 for dependent variables and 0·000147 for 
independent variables. These tests identified PC(34:1), PC(34:2) and PC-O(34:1) particularly clearly (Fig. 1). 
The abundance of these phospholipids was higher in MHG and SGA groups compared to Controls, howsoever 
fed (Fig. 1 and Supplementary Table 1). SM(39:1) showed differences between in utero groups among breastfed 
infants, but these differences were not significant among mixed-fed or formula-fed infants. Among breast-fed 
infants only, differences between the three in utero groups were also seen in the abundance of PC(38:4) and 
SM(36:2), but these were not significant according to the Bonferroni adjusted threshold.
Notably, the abundances of PC(34:1), PC(34:2) and PC-O(34:1) were higher in both SGA and MHG com-
pared to controls (Fig. 1). By contrast, the abundance of SM(39:1) is lower in SGA and MHG infants than in con-
trols. In order to verify the results of the sPLS-DA and univariate tests, we performed an unsupervised analytical 
approach (principal component analysis, PCA) on the whole dataset. The PCAs (Fig. 2) showed that all subgroups 
of SGA and MHG infants were distinct from Control infants, across all feeding types. Furthermore, PC(34:1) and 
PC(34:2) are the most important of these CBMs in distinguishing the groups, as they were more abundant than 
any other species measured (Fig. 1, full loadings shown in Supplementary Table 2).
Discussion
In this study, mass spectrometry was used to profile the phospholipids and triglycerides in the circulation of 
infants; statistical approaches were used to identify firstly variables and after more thorough testing candidate 
biomarkers (CBMs), that distinguish breastfed infants from those formula fed and conditions in utero simul-
taneously. These approaches identified PC(34:1) and PC(34:2) as the CBMs that represent the clearest differ-
ence in phospholipid metabolism, with PC-O(34:1) and SM(39:1) performing more moderately, but also being 
significant. However, all four of these lipids have the same head group (choline) and three of the four are very 
similar isoforms (34:1 or 34:2). This uniformity hints that these species may originate from a common process 
or under control of the same pathway. These species undoubtedly have structural roles in vivo, however, PCs are 
increasingly being recognised as having signalling functions as well, including these isoforms of PC31. In addition, 
SM(39:1) has recently been identified as a marker for dietary intake of fresh milk24. The PCs were more abun-
dant in the circulation of infants from abnormal uterine conditions (SGA and MHG) than in Controls, whereas 
SM(39:1) was less abundant than controls across all feeding types.
Evidence collected over the last decade has shown that an isoform of PC(34:1), PC(16:0/18:1), has been iden-
tified as an endogenous ligand (agonist) for the nuclear receptor PPARα (proxisome proliferator-activated recep-
tor alpha), found in hepatocytes. PPARα is a transcription factor regulating the expression of a number of genes 
involved in governing metabolism of triglycerides32 whose expression increases in foetal liver in pregnancies that 
progress normally33. Activation of PPARα is observed under fasting conditions34 and is characterised by increases 
Figure 2. Principal Component Analyses of lipid profiles of infants born as SGA or from mothers with 
gestational diabetes (green) against controls (red).
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in the catabolism of fatty acids and the abundance of peroxisomes32. In adults, it also decreases hepatic steatosis35 
but accelerates the development of the epidermal permeability barrier in the foetus36. PC(34:1) increases in abun-
dance by up to 100% between the control and both MHG and SGA groups in this study (Fig. 1). This suggests that 
activation of PPARα may be more common in the exposed groups. If true, one would therefore expect a faster rate 
of catabolism of fatty acids, and a weaker tendency of them being stored as triglycerides in SGA and MHG babies. 
An interaction such as this may form the basis for the metabolic programming effects observed by the conditions 
in utero and the feeding type afterwards.
We note that PC(34:1) appears as both a post natal nutritional CBM (i.e. for feeding type) and one that distin-
guishes conditions in utero. It is not clear from the present evidence whether this lipid is ubiquitous or has several 
functions. There is a plethora of evidence for a variety of phospholipids possessing even three or more functions 
simultaneously31,37,38. One possibility is that the structural differences between the control and exposed groups 
Control SGA MHG
n 40 34 59
Breastfed 16 18 25
Mixed feeding 13 8 18
Formula fed 11 8 16
Birth weight (Kg) 39 34 59
Mean 3.37 2.41 3.3
s.d. 0.38 0.24 0.37
     Range (Lowest) 2.65 1.86 2.72
     Range (Highest) 4.02 2.85 4.88
Significance
     against control group — 5.10E-09 0.63
      against SGA group 5.10E-09 — 5.10E-09
     against MHG group 0.63 5.10E-09 —
Gestational age (w) 40 33 59
Mean 39.84 39.64 39.05
s.d. 1.33 1.61 0.94
     Range (Lowest) 36.00 36.14 36.57
     Range (Highest) 41.86 43.00 41.43
Significance
     against control group — 0.76 7.04E-03
     against SGA group 0.76 — 0.08
     against MHG group 7.04E-03 0.08 —
No. male (%)
Breastfed 31 50 32
Mixed feeding 62 38 78
Formula-fed 27 38 88
Maternal age (years) 40 33 59
Mean 32.89 33.19 34.53
s.d. 5.42 4.68 4.34
     Range (Lowest) 19.53 23.15 22.69
     Range (Highest) 41.33 43.56 44.14
Significance
     against control group — 0.96 0.22
     against SGA group 0.96 — 0.40
     against MHG group 0.22 0.40 —
Maternal BMI 34 30 46
Mean 22.77 24.1 25.92
s.d. 4.29 4.88 6.05
     Range (Lowest) 17.68 19.22 17.33
     Range (Highest) 35.23 35.48 44.39
Significance
     against control group — 0.57 0.02
     against SGA group 0.57 — 0.30
     against MHG group 0.02 0.30 —
Table 2. Participant characteristics. The characteristics of the participants of the subset if the Cambridge Baby 
Growth Study II cohort used in this study. n = 133. Significance was calculated using a Tukey HSD post-hoc 
analysis. Maternal BMI was taken at or before conception. Maternal age is as at delivery.
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in this study have driven changes in the abundance of commonplace structural molecules such as PC, that also 
have other roles31.
The abundance of PC(18:0/18:1), an isoform of PC(36:1), is also different in breastfed infants in this study. 
The abundance of PC(36:1) is around 60% higher in both SGA and MHG groups than normal birth weight 
Controls, among infants receiving breastfeeding (Table 3). However, the abundance is similar in across in utero 
groups fed formula (Table 3). PC(18:0/18:1) is an endogenous agonist for another PPAR, PPARδ, with activation 
reducing the concentration of triglycerides in plasma post prandium and increasing fatty acid use in the periph-
ery39. However, there is also evidence that the two receptors are sufficiently specific such that PC(18:0/18:1) is not 
cross-reactivate with the receptor specific for PC(16:0/18:1)31.
These data therefore suggest that activation of PPARδ may be different in babies receiving formula from those 
receiving breastmilk. If true, the triglycerides consumed by babies ingesting breastmilk will have a shorter half-life 
(be in the circulation for a shorter time) than those only fed formulae.
Furthermore, a naturally-occurring, endogenously-produced oxidised form of PC-O(34:1) is a potent ago-
nist of PPARγ40. PPARγ is widely regarded as a key transcription factor in adipocyte differentiation41,42 and as 
PC-O(34:1) is much more abundant in infants from GDM pregnancies than controls, we might predict that more 
of the oxidised form (oxPC-O(34:1), which is commercially available) in circulo and that this leads to higher acti-
vation of PPARγ in SGA and MHG infants. This is significant because activation of PPARγ through an increase 
in the abundance of PC-O(34:1) provides a mechanism by which this species promotes adiposity. This may be 
important in long term metabolic health as there is now evidence that adiposity in adolescents is modulated by 
breastfeeding countering the deleterious effects of a PPARγ43.
More generally, how PPARs are expressed in the foetus can be influenced by maternal diet and obesity44,45. 
Specifically, an animal model has been shown that intra-uterine growth restriction decreases the expression of 
PPARγ in the lung46 but increases it in adipocytes47.
The summative effect of both the putative increased abundance of agonists for PPARα, PPARδ and PPARγ and 
changes to their expression is unclear at present, however we expect a mixture of effects with respect to healthy 
systems as the catabolism of fatty acids and storage of TGs is favoured. This has implications for the relationship 
between conditions in utero and shortly thereafter, and later development. Further work is required to establish 
whether the CBMs identified in this study have a functional or metabolic programming influence on metabolism 
in infants who experienced different conditions in utero. This could be achieved by another study with increased 
statistical power but also follow-up samples and meta-data. Further work is also required to determine the origin 
and an understanding of how the abundance of such species is controlled, either by the infant’s system or the 
maternal one.
The sPLS-DAs used to identify CBMs can also be used to assess how similar the individual members of the 
groups are to one another. For example, the formula-fed infants in both MHG and SGA groups appear to be far 
more homogeneous than either the mixed or breastfed groups (Supplementary Fig. 3). This raises questions about 
the variety of phospholipid and triglyceride profiles in breastmilk, and their relationship with the mothers’ diet. A 
larger sample size in a different group of individuals is required to investigate this. However, these results suggest 
that the metabolic activity in formula-fed SGA and MHG infants is more homogeneous than other groups, hint-
ing that a narrower range of factors shapes the lipid profile found in their circulation.
Lastly, recent work on the lipid and triglyceride composition of infant formula suggests that this type of die-
tary intake varies considerably by manufacturer, manufacturing site and target demographic48. This may explain 
some of the heterogeneity in the groups fed formula. Several of the most abundant phospholipid species were 
similar across formulae, though the triglyceride profiles of formula and fresh milk were distinct. This suggests 
that further study of the relationship between lipid metabolism following the feeding of infant formula, and in a 
high powered manner, is required.
The present study represents a pilot, mechanistic-type investigation of the relationship between conditions in 
utero and later feeding. To our knowledge it is the first of its kind. It is limited in the manner that is typical of pilot 
studies (e.g. modest statistical power). Recent work on infant formula has shown that it is a varied and compli-
cated mixture, suggesting that the traditional classification of ‘formula-fed’ used in the present study and many 
others is a general one. However, the present study is capable of suggesting which of the comparisons are more 
important and thus which are of principal interest for further studies, both clinical and mechanistic.
Conclusion
In this study, the hypothesis that the lipid and triglyceride metabolism in infants is shaped by antenatal conditions 
(including glucose supply) and postnatal nutrition was tested in a pilot cohort by profiling the phospholipid, 
triglyceride and sterol fractions in the circulation of infants three months post partum. Three separate statistical 
methods indicate that the abundance of a small number of phospholipids with a narrow range of structures 
(PC34:1), PC(34:2) and PC-O(34:1)) best distinguishes the groups of individuals. We note that phospholipids 
with this molecular structure have an important role in triglyceride metabolism in humans, through interaction 
with PPARs. Furthermore, the evidence from the separate analyses in this study indicates that the feeding type 
applied to infants is as important for the phospholipid profile observed in infants at three months post partum as 
the effect of the in uterine conditions associated with SGA and MHG. This study therefore provides evidence that 
both feeding and conditions in utero shape short-term phospholipid metabolism in early life. Furthermore, the 
similar nature of the pattern of abundance of CBMs between exposed groups (SGA and MHG) indicate that the 
shifts in lipid metabolism may be similar between these groups.
The precise role or effects in infants of the candidate biomarkers identified in this study is not yet fully under-
stood. Further work may explore how changes in phospholipid metabolism can be used to correct the metabolic 
consequences of unfavourable conditions in utero.
7Scientific RepoRtS |         (2019) 9:14321  | https://doi.org/10.1038/s41598-019-50693-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
Experimental Methods
Study design. This pilot study was designed to determine what, if any, differences in phospholipid, sterol 
and/or triglyceride metabolism there are between infants as a factor of both conditions in utero and feeding in the 
first three months of life. This necessitated a suitable array of participants, consistent sample collection, detailed 
measurement of molecular abundance and statistical analyses.
Cohort. We used a subset of infant participants from the Cambridge Baby Growth Study II, characterised in 
Table 2. Only samples from singleton births were used. This is a prospective observational birth cohort, focussing 
on the antenatal and early postnatal determinants of infancy growth (22) Mothers were recruited during early 
pregnancy from a single antenatal centre in Cambridge.
There were three groups of infant participants according to conditions in utero: (a) infants being born small 
for gestational age (SGA group), (b) a normal birth weight (Control group) and (c) a normal birth weight group 
who had exposed to maternal hyperglycaemia (MHG group; mothers of infants in this group were diagnosed 
according to IADPSG thresholds for GDM)49. There were three groups within each of these in utero groups, based 
on feeding mode. Feeding groups were of breastfed, formula-fed or infants receiving a mixed intake (Table 2). 
We were not able to determine the relative proportions of the two due to well-known experimental difficulties in 
establishing the volume of milk consumed during breast feeding.
Ethics. All procedures were performed in accordance with the ethical standards of the institutional and/or 
national research committee and with the 1964 Helsinki declaration and its later amendments or comparable 
ethical standards. All mothers gave informed written consent and the study was approved by the Cambridge local 
research ethics committee (LREC 11/EE/0068). Class membership of samples were blinded and so technicians 
and analysts were not aware of which participants fell into which groups until after the lipid profiles were availa-
ble, and then only by participant number.
Reagents and standards. Solvents of at least HPLC grade were purchased from Sigma-Aldrich Ltd. 
(Gillingham, Dorset, UK) and were not purified further. Lipid standards were purchased from Avanti Polar lipids 
(Alabaster, AL; through Instruchemie, Delfzijl, NL) and used without purification. Consumables were purchased 
from Sarstedt AG & Co (Leicester, UK).
Sample collection. Samples from the three in utero groups were drawn from infants (n = 133) who par-
ticipated in the Cambridge Baby Growth Study II and collected between 2011 and 2013. Their infants were seen 
at birth by trained research nurses and followed-up at 3 months. Blood was collected by a heel prick, spotted 
immediately on untreated filter paper cards (Ahlstrom 226; ID Biological Systems, Greenville, South Carolina) 
and dried at room temperature overnight. Dried blood spots were stored under a small, sealed air atmosphere at 
−80 °C. Samples were collected during morning appointments (0900–1130). Infancy feeding (exclusive breast-, 
mixed or exclusive formula-feeding) was assessed by questionnaire at age 3 months.
Lipid extraction. The phospholipid, triglyceride and sterol fractions were isolated together using a 
method reported recently50. Briefly, dried blood spot samples, as 3·2 mm diameter discs, were placed along 
with blank and Quality Control samples (QCs) in the wells of a glass coated 2.4 mL/well ninety-six-well 
plate (96w plate; Plate+™, Esslab, Hadleigh, UK). Water (100 μL, MilliQ) was added to each of the wells, 
followed by methanol (250 μL, HPLC grade, spiked with 0·6 μM 1,2-di-O-octadecyl-sn-glycero-3-p
hosphocholine, 1·2 μM 1,2-di-O-phytanyl-sn-glycero-3-phosphoethanolamine, 0·6 μM C8-ceramide, 0·6 μM 
N-heptadecanoyl-d-erythro-sphingosylphosporylcholine, 6·2 μM undecanoic acid, 0·6 μM trilaurin), followed 
by tert-butyl methyl ether (TMBE, 500 μL). The plates were then sealed (aluminium microplate sealing tape), agi-
tated (10 min, 600 rpm) and centrifuged for 10 min at 3·2 k × g. A 96-head micro-dispenser was used to transfer 
200 μL of the organic solution to a glass-coated 240 μL 96w plate (Plate+™, Esslab, Hadleigh, UK). The plate was 
transferred to a Genevac EZ-2 evaporator (Genevac Ltd., Ipswich, UK) and dried. The samples were reconstituted 
Mean StDev T-test
Loadings values
PC1 PC2
Control (BF) 14·072 2·250
SGA (BF) 25·106 4·530 1·573 × 10−9 0·1026 −0·0862
MHG (BF) 25·070 7·010 6·370 × 10−8 0·1270 −0·0833
Control (M) 15·099 2·054
SGA (M) 26·355 3·995 3·440 × 10−5 0·1356 −0·0806
MHG (M) 24·438 4·271 1·545 × 10−8 0·1189 −0·0754
Control (FF) 15·415 2·706
SGA (FF) 14·230 2·172 3·409 × 10−7 0·1284 0·0072
MHG (FF) 14·072 2·250 1·701 × 10−8 0·0947 −0·0588
Table 3. Abundance of PC(36:1). Mean and standard deviation of abundance of PC(36:1), p-value associated 
with the difference between exposed and control samples and the loadings in the PCAs (Fig. 2). PC(36:1) is not 
a CBM due to the similar abundance across formula fed groups. BF, breastfed; M, mixed feeding; FF, formula-
fed.
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(TBME, 25 μL and MS-mix [7.5 mM ammonium acetate in IPA:CH3OH (2:1)], 90 μL) of using a Hydra Matrix, 
after which the plate was sealed and stored at −20 °C.
Mass spectrometry. All samples were infused into an Exactive Orbitrap (Thermo, Hemel Hampstead, UK), 
using a Triversa Nanomate (Advion, Ithaca US) and a mass resolution of 100,000. Samples were ionised at 1·2 kV. 
The Exactive started acquiring data 20 s after sample aspiration began. After 72 s of acquisition in positive mode 
the Nanomate and the Exactive switched to negative mode, decreasing the voltage to −1·5 kV. The spray was 
maintained for another 66 s, after which the analysis was stopped and the tip discarded, before the analysis of the 
next sample began. Throughout the analysis the sample plate was kept at 15 °C. Samples were run in row order.
The phospholipid and triglyceride signals obtained were relative abundance (‘semi-quantitative’), with the 
signal intensity of each lipid expressed relative to the total lipid signal intensity, for each individual, per cent 
(%). Raw high-resolution mass-spectrometry data were processed using XCMS (www.bioconductor.org) and 
Peakpicker v 2.0 (an in-house R script).
Statistical methods. In order to identify which individual molecular species best represented the differ-
ences in the lipid metabolism between the various groups, we employed several statistical methods. All mul-
tivariate analyses (MVA) except Random Forest were carried out using Metaboanalyst 4.051. Random Forest 
classifications were carried out using R. Univariate tests were carried out using Microsoft Excel 2013. Significance 
thresholds were corrected for multiple testing and p-value cut offs used were 0·00271 for dependent variables and 
0·000147 for independent variables.
The first stage of our analysis was to augment a previous analysis with the lipid profile collected in negative 
ionisation mode. The previous analysis used species detected in positive mode only25. This employed the same 
unsupervised test used in previous work, viz. a Principal Component Analysis (PCA). This indicated a fuller 
range of detectable molecular species that were associated with feeding type. The second stage was designed to 
test whether conditions in utero (SGA, MHG, Control) had an effect on lipid metabolism that was generally inde-
pendent of that of feeding. A Random Forest classification was used for this test, using three groups and 10k trees. 
The third stage was candidate biomarker discovery. This comprised two parts. First, a sparse Partial Least Squares 
Discriminant Analysis was used to identify individual variables that distinguished the groups from one another, 
followed by (univariate) T-tests to identify which candidate biomarkers (CBMs) were significantly different in 
abundance. Second, an unsupervised MVA statistical test was used to verify the ranked importance of the CBMs 
identified in the first stage (supervised MVA and univariate tests). The type of MVA was unsupervised (PCA) 
because this offers an orthogonal approach to identifying variables but also to minimise bias.
Data Availability
The datasets generated during and analysed during the current study are available from the corresponding author 
on reasonable request.
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